Spirulina

ApprovedSmall molecule

TTanta University

Spirulina is one of 81 small molecule programs targeting Chronic Periodontitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic PeriodontitisActive, not recruiting

PeriodontitisActive, not recruiting

Beta-ThalassemiaActive, not recruiting

Chronic PeriodontitisApproved

Active, not recruiting

PeriodontitisPreclinical

Active, not recruiting

Beta-ThalassemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

138 competitors in Periodontitis

#DrugCompanyPhaseTrials

Peridex

DDexcel Pharma Technologies Ltd.

Phase 3

10 2

Acanya

Pfizer

Phase 3

1 3

Curcumin

Merck & Co.

Phase 3

1 4

Cysteine Hydrochloride

Novartis

Phase 2

1 5

Bayer Aspirin

Bayer

Phase 2

1 6

Spirulina

TTanta University

Approved

1 7

Calcium Hydroxide

MMansoura University

Phase 3

2 8

Glutamine

Sanofi

Phase 2

1 9

Atorvastatin Calcium

Merck & Co.

Phase 2

1 10

Calcium Intravenous Infsuion

MMansoura University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Periodontitis1 trial

Effect of Arthrospira Platensis (Spirulina) as an Adjunct to Scaling and Root Planing on Salivary Antioxidant Levels in Chronic Periodontitis Subjects

Completed·TTatyasaheb Kore Dental College·Phase 4·NCT02886676·70 enrolled

Periodontitis1 trial

Effect of Spirulina on Periodontitis

Completed·KKafrelsheikh University·N/A·NCT06016933·40 enrolled

Beta-Thalassemia1 trial

Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia

Completed·TTanta University·N/A·NCT02671695·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Spirulina. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Spirulina compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Spirulina. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tanta University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TTanta University

Spirulina

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Periodontitis1 trial

Periodontitis1 trial

Beta-Thalassemia1 trial

References

Drug Info

Quick Facts

Related News